Medial Earlysign
Healthcare company using AI to predict and prevent high-risk diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | $30.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Medial EarlySign, founded in 2009 by machine learning pioneers, specializes in analyzing clinical data to detect early signs of serious diseases such as cancer. The company collaborates with leading health systems in the United States, Europe, and Asia, leveraging a wide array of clinical data including claims and advanced diagnostics. Medial EarlySign's technology organizes and analyzes clinical data using machine learning and artificial intelligence, transforming it into actionable clinical insights. The company serves a diverse range of clients including healthcare providers, labs, payers, diagnostics, pharma, and life sciences sectors. Operating in the healthcare market, Medial EarlySign's business model focuses on providing advanced data analytics solutions to improve early disease detection and patient outcomes. Revenue is generated through partnerships and service agreements with healthcare organizations.
Keywords: AI, machine learning, clinical data, early detection, healthcare, diagnostics, data analytics, chronic diseases, medical insights, health systems.